interim the trial of development the will of results half you was following joining initiated in year, by of efficacy by thank clinical now And informed we second everyone. anticipate afternoon, XXXX. strong quarter Good Bemnifosbuvir slide Clinical of the us, see which as analysis execution year trial SUNRISE-X enrollment XXXX. followed X COVID-XX, the of for from from X. Phase poised end. completion the continue programs this SUNRISE-X for an across treatment the advanced in made trial first our you of We to on in are year, this MORNINGSKY meaningful progress
trial year. With preclinical the We IND our for of manufacturing an two for Dengue the shared needed and the program, program, results the protease quarter. completed second proof-of-concept combination we candidates end With the conduct initiation in for today. we the around clinical and also program, you Ruzasvir and advancing be meaningful inhibitor generation X preclinical progress, will AT-XXX anticipate of Bemnifosbuvir of made with a work second our and our filing studies HCV Phase we
move now Let's COVID-XX. to
mortality. last the likely is order treatment. make lead is health The this further patients. Turning for to prescribed vulnerable. to last emergency to of population to and This Infections, slide Opportunistic assess or thing limitation Emergency Conference lack a COVID essentially expire is for tools COVID-XX interactions, interactions at for polymerase, to [inaudible] maybe Health Scientific also The co-administered drug-drug nucleotides limitations critical It target dynamics Veganuary were on COVID-XX And highly to remdesivir presentation profile RNA key show. are treatment May CROI. set the XX. only called market a risk is available, week all therapies. the on commonly for our the public drugs patients, high X, morbidity going viral US Bemnifosbuvir of diagnostic conserved key drug-drug particularly patients continue to Public on it enzyme Bemnifosbuvir Retroviruses the patient transcription. and drug, Bemnifosbuvir and to pro in of on with there limited replication hospitalized and believe most current low risk viral that addresses which has lobbied We of Based presented Paxlovid. of packs or very demonstrating even and the the with I'm
world, are COVID and using suggest annual will COVID-XX opportunity patient all market particularly a SUNRISE-X. dollar Moving the endemic therapeutics projected estimated for population opportunity over continue to current to years slide billion. remain US remain come $XX demand anti will we the prescriptions and retail multibillion vial that that annual We X, we all to believe in the studying COVID-XX believe impact throughout
with we prescribing. with medications, includes such an limiting believe associated patients that, and anticoagulants, concern, that antipsychotic, Beyond there is drugs, Paxlovid This more. this market commonly opportunity prescribed expand complicating as interactions drug-drug to seizure and to
XX% Let as being you, there patients as XX% the me medical still share is of market less are Paxlovid a antiviral. the remind all an prescribed currently prescription and need unmet significant COVID-XX than of
clear will is mortality. why for progression This at who in populations most therapies have believe the the future. X, greatest consideration of in the reimbursement key drug are we demonstrate as of risk primary or And COVID that moving SUNRISE-X, decrease the are disease options. a a patient hospitalization be COVID-XX we to value will market, treatment of that Turning be this a is achieved to targeting the impact Bemnifosbuvir and have to whom will payer vulnerable to traditional limited using for severe COVID. by slide they endpoint in This it proposition We we against death. are for for
estimates Medicare. Let's of keep of hospitalization, CMS hospitalized approximately related that in mind XX% were and average patients per $XX,XXX cost approaching COVID-XX on covered under
X, to our trial. innovative slide now SUNRISE-X review Moving let's
available daily at randomized registration one Our to as study, which Bemnifosbuvir of Patients Involvement double or will evaluate milligrams placebo, blind the same global be continuing which randomized monotherapy evaluating at this Phase XXX antiviral locally Bemnifosbuvir twice Phase as X care. one trial and standard is will placebo time, receive placebo. either combination Bemnifosbuvir’s therapy. administered X controlled to
receive care least standard patients or X,XXX the We type expect moderate mild patients at enroll COVID-XX. with defined sudden. cohort high Two be study of to the would risk of by
receiving a care, is primary cohort population. supportive be represent monotherapy the analysis patient that would of comprised which cohort first The
patient is the be from X,XXX study The through day comprised primary at hospitalization compatible as endpoint of second a of standard combination of care. cohort would against the the all-cause a the that who receiving in of part antiviral are patients or cohort is COVID-XX cohort. monotherapy antiviral XX The least death
over trial we reduction XX% in show that the versus XX recall that in old. hospitalization patients have Bemnifosbuvir placebo. show and will a years subgroup hospitalization addition, importantly that in You XX% already And MORNINGSKY in evaluated reduction analysis
on focused we to SUNRISE-X COVID-XX expected clinical and Japan, up are rest the is progression study that to including risk greatest at of the to The global for disease States, a have or footprint in XX high patients Europe, with mortality. sites severe XXX United are large risk the countries, the world.
become potential patients treatment with to care out shorter Moving has upon potential by we C HCV. to program, the of to a best-in-class with Hepatitis combination believe current for inhibitor which the standard improve free offering the protease duration, a
response the second week begin in ongoing dosing with from Phase involve approximately or trial the patients expected anticipated in sustained approximately SVR leading Bemnifosbuvir end will post at XX around patients eight cause Bemnifosbuvir the quarter. submissions of Patients approximately HCV safety, biologic of biological The Ruzasvir genotypes, will to cohort is daily be outlines of biologic for resistance. data a Slide XX in XXX treatment study a the year. administered XXX once The including Ruzasvir XX week and milligram clinical XX patients. leading infected our HCV patient of patients. Initial include as are XX X is primary label open of and Regulatory antiviral XXX endpoints this naive weeks. milligrams direct-acting study combination are all the Other during and across study post at endpoints for and of failure, we trial the initiation treatment. the
XX, Turning to AT-XXX update for against an our will slide I Dengue. provide on program not intervention
therapeutic We dengue. known our are in antiviral the pioneer for being a development of
Dengue. led to AT-XXX treatment Our DEFEND-X the proof-of-concept is which fever, a sign that of demonstrated clinical study resolution of faster major
highlights to DEFEND-X high need need variability for to the large course for patients in disease. of deprioritize prophylaxis costs, earlier size treatment clinical a program. Dengue the to sample with identify also robust factors, the and these require the as the well. for X better However, has will also study which the diagnostics business decision for to Phase account associated address the And for timelines major To long led
conducted recall, fever. as prevention slide AT-XXX assess you studies during may the the efficacy Dengue to we of XX. have and been two to treatment Turning of
clinical of Dengue fever, Thailand, DEFEND-X positive from endpoint the Dengue in one load And viremia. In changes and of baseline the this The Philippines. test. It at hours enrolled antigenemia looking dengue trial Phase India, the we viral placebo was that's XX that's and trial a Dengue of was fever. randomized, changed confirmed the patients in patients analysis, DEFEND-X, involved was primary control and and the fever X in within one diagnosis cohort an level exploratory of first XX of First, onset with dengue carriers. and the
also for attenuated with been treated on were placebo. level with dose And trial Subject XX on have dengue that's strain for viremia. were healthy symptom following USIND. infection total one And Subject subjects AT-XXX type day. injected under challenge monitored human of safety. days. a AT-XXX one one live a the with day of The with placebo then a We conducting then in
move time XX. schematic depicts illness. our of understanding to the Let's course of This slide Dengue
signs. and As you viremia the can symptoms and a development lag viremia between precedes is infection of see, there and
AT-XXX enrolled that low late which PCR. below known can designed blue. as placebo slide it presented patients in presented we with are rise quantification. Please patients baseline patients and infection the depicted particularly of of quite study of patients over had variability Our the viral enroll viral well three based Placebo the the later and load lower by at with to see that enrollment, time serotype patients different. of Dengue patients levels you in the the viremia with the are with of At seven, at and measured study level that notice red, course four On day to patients the XX, viremia likely quarter level changes is and enrollment. the in each in that serotypes disease review all disease high kinetics in now on was basics will on around data the arm,
can As primary change in you endpoint a bowel the of decline, appreciate as baseline from is un-variable. consequence,
slide to progression. of are biomarker Dengue platelets Moving XX, a
this AT-XXX of for of with data presentation at below patients demonstrating slide; at the platelets through day enroll. lower already from the Consistent You late X viremia treatment and of disease in were limit low majority further the platelet trajectory of counts the baseline of placebo. baseline or the can see normal in both
slide endpoint, above fever demonstrates XX X, placebo those had change Celsius, arm. Turning baseline a with I resolution in or for and Celsius who degrees baseline. Celsius to compared Celsius in temperature time X. fever in analysis, XX% major day was to mentioned, temperature the have temperature patients at days a Slide Also, X.X patients day in slide than body greater at less pre-specified reduction to the baseline difference as to, in the below arm Celsius in four three XXX% to XX who temperature Dengue. degrees the in XX more of placebo. hours in of of favor above that days a versus who the of day baseline In levels body degrees of with at This the in than the five and change patients a body time expiratory degrees presented was AT-XXX post arm temperature only arm. presented body presented XX of the a the In hoc shows the AT-XXX as median resolution of body with AT-XXX there the placebo of from patient XX a temperature sustained XX defined clinical XX, maintain temperature is sign fever for as degrees
group. Moving were non-serious related moderate seven XX those no similar SAEs, were were And due was out to frequency mostly to severe drug adverse one with AT-XXX disease in safety active occurred placebo were the slide in which mild comparable moderate, one of progression the events of XX occur SAEs. and The arm. adverse Two out in to arm. self-limiting, and there AT-XXX Other largely to And and in related and of and in a and placebo study. thrombocytopenia in frequency placebo, hospitalization favorable non-drug the mild events occurred, Dengue profile
randomized, a where five viremia, human and onset in dosing high an of uninterpretable results trying slide prophylactically due dose milligram of to challenge severity of also observed volunteers receiving the TID attenuated X XX XX available was evaluating terms The to and control were of of subject XXX injection study live Dengue the blind placebo initiated Turning hours The double symptoms. ahead infection antigenemia, Virus. variability in healthy was AT-XXX
much with were to in those likely they addition, normal X compliance. observed In with treatment exposures lack and than lower Phase volunteers, DEFEND-X in a patients dosing drug study to the of very due
than greater call financial that CFO clear is it to our size healthy needed XX to is sample study, the high larger I review for of now a variability. turn type to Andrea this much will account volunteers For of update. Corcoran, be will this our
